Especially, based on the important function of SYK in hematopoietic cells, the therapeutic action of SYK inhibitors has been confirmed in multiple myeloma, such as acute myeloid leukemia and chronic lymphocytic leukemia [1, 59, 60]. The gene discussed is SYK; the disease is B-cell chronic lymphocytic leukemia.